Large-Cap Biopharma
Companies whose principal business activity is classified as “Large-Cap Biopharma”.
Scope: Business-model basket of diversified large-cap drug makers.
Leadership as of 2026-10-27: Leading. Relative to SPY: 5 sessions +1.9pp, 21 sessions +6.1pp, 63 sessions +6.3pp. Participation 75%; 8 of 8 members eligible.
- 21-session excess +6.1pp ≥ +2.0
- 63-session excess +5.1pp (robust) ≥ +2.0
- 21-session excess without the strongest member +3.9pp > 0
- 75% of window members beat SPY over 21 sessions
Economic family: Biotechnology
Member companies
Related themes
- Neuro / CNS: Neutral — 21-session vs SPY −0.2pp, participation 43%
- Molecular Diagnostics: Weakening — 21-session vs SPY +15.9pp, participation 80%
- Immunology & Inflammation: Lagging — 21-session vs SPY −3.6pp, participation 29%
- Rare & Genetic Disease: Lagging — 21-session vs SPY −3.6pp, participation 32%
- RNA Therapeutics: Lagging — 21-session vs SPY −4.2pp, participation 40%
- Oncology: Lagging — 21-session vs SPY −8.2pp, participation 32%
- Gene Therapy: Lagging — 21-session vs SPY −16.6pp, participation 0%
- Targeted Protein Degradation: Tracked (too few stocks for a leadership state) — 21-session vs SPY +2.4pp, participation 67%